Health
Study supports continuing phase 3 trials of Ad26.COV2.S SARS-CoV-2 vaccine – News-Medical.Net
An international team of researchers has provided further evidence to confirm the immunogenicity and efficacy of a recombinant adenovirus vaccine currently being…
An international team of researchers has provided further evidence to confirm the immunogenicity and efficacy of a recombinant adenovirus vaccine currently being tested in phase 3 trials for its ability to protect against infection with severe acute respiratory coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).
The vaccine comprises a recombinant adenovirus serotype 26 (Ad26) vaccine vector expressing a stabilized form of the SARS-CoV-2 spike antigen that the…
-
Noosa News20 hours agoHow Lily Steele-Park took her rapist to court and won
-
Noosa News24 hours agoStar’s Brisbane casino has been in the headlines for months: What’s the latest?
-
Business23 hours ago5 things to watch on the ASX 200 on Tuesday 8 July 2025
-
Noosa News21 hours agoE-biker charged with riding dangerously, assaulting cop